HRP20050432B1 - Novel medicaments for the treatment of chronic obstructive pulmonary diseases - Google Patents

Novel medicaments for the treatment of chronic obstructive pulmonary diseases

Info

Publication number
HRP20050432B1
HRP20050432B1 HR20050432A HRP20050432A HRP20050432B1 HR P20050432 B1 HRP20050432 B1 HR P20050432B1 HR 20050432 A HR20050432 A HR 20050432A HR P20050432 A HRP20050432 A HR P20050432A HR P20050432 B1 HRP20050432 B1 HR P20050432B1
Authority
HR
Croatia
Prior art keywords
alkyl
treatment
chronic obstructive
obstructive pulmonary
pulmonary diseases
Prior art date
Application number
HR20050432A
Other languages
English (en)
Croatian (hr)
Inventor
Hoenke Christoph
Lustenberger Philipp
Rudolf Klaus
Bouyssou Thierry
Buettner Frank
Konetzki Ingo
Pestel Sabine
Schnapp Andreas
Schollenberger Hermann
Schromm Kurt
Heine Claudia
Original Assignee
Boehringer Ingelheim Pharma Gmbh & Co.Kg.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32185709&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20050432(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Pharma Gmbh & Co.Kg. filed Critical Boehringer Ingelheim Pharma Gmbh & Co.Kg.
Publication of HRP20050432A2 publication Critical patent/HRP20050432A2/xx
Publication of HRP20050432B1 publication Critical patent/HRP20050432B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HR20050432A 2002-11-15 2003-11-11 Novel medicaments for the treatment of chronic obstructive pulmonary diseases HRP20050432B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10253282A DE10253282A1 (de) 2002-11-15 2002-11-15 Neue Arzneimittel zur Behandlung von chronisch obstruktiver Lungenerkrankung
PCT/EP2003/012565 WO2004045618A2 (de) 2002-11-15 2003-11-11 Neue arzneimittel zur behandlung von chronisch obstruktiver lungenerkrankung

Publications (2)

Publication Number Publication Date
HRP20050432A2 HRP20050432A2 (en) 2006-06-30
HRP20050432B1 true HRP20050432B1 (en) 2012-01-31

Family

ID=32185709

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20050432A HRP20050432B1 (en) 2002-11-15 2003-11-11 Novel medicaments for the treatment of chronic obstructive pulmonary diseases

Country Status (38)

Country Link
EP (2) EP2025338A1 (enrdf_load_stackoverflow)
JP (1) JP4317138B2 (enrdf_load_stackoverflow)
KR (1) KR101092247B1 (enrdf_load_stackoverflow)
CN (3) CN1713914A (enrdf_load_stackoverflow)
AR (2) AR041969A1 (enrdf_load_stackoverflow)
AT (1) ATE430569T1 (enrdf_load_stackoverflow)
AU (1) AU2003285326B2 (enrdf_load_stackoverflow)
BE (1) BE2014C016I2 (enrdf_load_stackoverflow)
BR (1) BRPI0316264B8 (enrdf_load_stackoverflow)
CA (1) CA2506082C (enrdf_load_stackoverflow)
CO (1) CO5570670A2 (enrdf_load_stackoverflow)
CY (2) CY1110500T1 (enrdf_load_stackoverflow)
DE (2) DE10253282A1 (enrdf_load_stackoverflow)
DK (1) DK1562603T3 (enrdf_load_stackoverflow)
EA (1) EA008665B1 (enrdf_load_stackoverflow)
EC (1) ECSP055774A (enrdf_load_stackoverflow)
ES (1) ES2326878T7 (enrdf_load_stackoverflow)
FR (1) FR14C0049I2 (enrdf_load_stackoverflow)
HR (1) HRP20050432B1 (enrdf_load_stackoverflow)
HU (1) HUS1400011I1 (enrdf_load_stackoverflow)
IL (1) IL167900A (enrdf_load_stackoverflow)
LT (1) LTC1562603I2 (enrdf_load_stackoverflow)
LU (1) LU92433I2 (enrdf_load_stackoverflow)
ME (1) ME00354B (enrdf_load_stackoverflow)
MX (1) MXPA05005081A (enrdf_load_stackoverflow)
MY (1) MY136034A (enrdf_load_stackoverflow)
NL (1) NL300650I2 (enrdf_load_stackoverflow)
NO (2) NO334314B1 (enrdf_load_stackoverflow)
NZ (1) NZ540661A (enrdf_load_stackoverflow)
PE (1) PE20040694A1 (enrdf_load_stackoverflow)
PL (1) PL212238B1 (enrdf_load_stackoverflow)
PT (1) PT1562603E (enrdf_load_stackoverflow)
RS (1) RS51607B (enrdf_load_stackoverflow)
SI (1) SI1562603T1 (enrdf_load_stackoverflow)
TW (1) TWI343812B (enrdf_load_stackoverflow)
UA (1) UA81276C2 (enrdf_load_stackoverflow)
WO (1) WO2004045618A2 (enrdf_load_stackoverflow)
ZA (1) ZA200502246B (enrdf_load_stackoverflow)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7056916B2 (en) 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
ES2380370T3 (es) 2004-04-22 2012-05-11 Boehringer Ingelheim International Gmbh Combinaciones farmacológicas que contienen benzoxazina para el tratamiento de enfermedades de las vías respiratorias
DE102004019539A1 (de) * 2004-04-22 2005-11-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittel zur Behandlung von Atemwegserkrankungen
CA2565243A1 (en) * 2004-05-13 2005-11-24 Boehringer Ingelheim International Gmbh Hydroxy-substituted benzo-condensed heterocycles for use as beta agonists in the treatment of respiratory diseases
DE102004024454A1 (de) * 2004-05-14 2005-12-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Enantiomerenreine Betaagonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
US20050256115A1 (en) * 2004-05-14 2005-11-17 Boehringer Ingelheim International Gmbh Aerosol formulation for the inhalation of beta-agonists
US7745621B2 (en) 2004-05-14 2010-06-29 Boehringer Ingelheim International Gmbh Long acting bronchodilators for the treatment of respiratory diseases
DE102004024452A1 (de) * 2004-05-14 2005-12-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Aerosolformulierung für die Inhalation von Betaagonisten
DE102004024451A1 (de) * 2004-05-14 2005-12-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulverformulierungen für die Inhalation, die Enantiomerenreine Betaagonisten enthalten
US7220742B2 (en) 2004-05-14 2007-05-22 Boehringer Ingelheim International Gmbh Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
DE102004024453A1 (de) * 2004-05-14 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue langwirksame Bronchodilatoren zur Behandlung von Atemwegserkrankungen
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
DE102004045648A1 (de) * 2004-09-21 2006-03-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Betamimetika zur Behandlung von Atemwegserkrankungen
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
DE102005007654A1 (de) 2005-02-19 2006-08-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue langwirksame Betamimetika zur Behandlung von Atemwegserkrankungen
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
DE102005030733A1 (de) * 2005-07-01 2007-01-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittelkombinationen zur Behandlung von Atemwegserkrankungen enthaltend langwirksame Beta-2-Agonisten und wenigstens einen weiteren Wirkstoff
BRPI0614290A2 (pt) 2005-08-08 2011-03-22 Argenta Discovery Ltd derivados de biciclo [ 2.2.1 ] hept-7-ilamina e seus usos
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
MX2008001976A (es) * 2005-08-15 2008-03-25 Boehringer Ingelheim Int Procedimiento para la preparacion de betamimeticos.
US20070088030A1 (en) * 2005-10-10 2007-04-19 Barbara Niklaus-Humke Aerosol formulations for the inhalation of beta-agonists
TWI396541B (zh) 2005-10-10 2013-05-21 Boehringer Ingelheim Int 用於治療呼吸疾病之新穎藥物組合
BRPI0617485B8 (pt) 2005-10-21 2021-05-25 Novartis Ag anticorpo anti-il-13 humano isolado, composição farmacêutica e uso do referido anticorpo
JP2009514933A (ja) * 2005-11-09 2009-04-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 吸入用エアロゾル製剤
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
EP1986644A1 (de) * 2006-02-16 2008-11-05 Boehringer Ingelheim International GmbH Arzneimittelkombinationen zur behandlung von atemwegserkrankungen
PE20080142A1 (es) 2006-03-15 2008-04-14 Boehringer Ingelheim Int Beta-agonistas enantiomericamente puros y sus procedimientos de preparacion
ATE549337T1 (de) 2006-04-21 2012-03-15 Novartis Ag Purinderivate zur verwendung als adenosin-a2a- rezeptoragonisten
CA2660192A1 (en) * 2006-08-07 2008-02-14 Boehringer Ingelheim International Gmbh Novel enantiomeric pure beta agonists, method of manufacture and use as a medicament thereof
UY30542A1 (es) * 2006-08-18 2008-03-31 Boehringer Ingelheim Int Formulacion de aerosol para la inhalacion de agonistas beta
UY30543A1 (es) * 2006-08-18 2008-03-31 Boehringer Ingelheim Int Formulacion de aerosol para la inhalacion de beta- agonistas
WO2008037477A1 (en) 2006-09-29 2008-04-03 Novartis Ag Pyrazolopyrimidines as p13k lipid kinase inhibitors
CA2667962A1 (en) 2006-10-30 2008-05-08 Novartis Ag Heterocyclic compounds as antiinflammatory agents
NZ577939A (en) 2007-01-10 2011-03-31 Irm Llc Compounds and compositions as channel activating protease inhibitors
BRPI0807806A2 (pt) * 2007-01-25 2014-06-17 Boehringer Ingelheim Int " processo para a fabricação de beta-miméticos ".
AU2008248598B2 (en) 2007-05-07 2011-11-17 Novartis Ag Organic compounds
EP2231280B1 (en) 2007-12-10 2016-08-10 Novartis AG Amiloride-like Pyrazine-carboxamides as ENaC blockers
CA2711637A1 (en) 2008-01-11 2009-07-16 Novartis Ag Pyrimidines as kinase inhibitors
JP2011522860A (ja) 2008-06-10 2011-08-04 ノバルティス アーゲー 上皮性ナトリウムチャネルブロッカーとしてのピラジン誘導体
US8236786B2 (en) 2008-08-07 2012-08-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
WO2010076553A1 (en) 2008-12-30 2010-07-08 Dr. Reddy's Laboratories Ltd Sulfonamide compounds for the treatment of respiratory disorders
PL2391366T3 (pl) 2009-01-29 2013-04-30 Novartis Ag Podstawione benzimidazole do leczenia gwiaździaków
WO2010150014A1 (en) 2009-06-24 2010-12-29 Pulmagen Therapeutics (Inflammation) Limited 5r- 5 -deuterated glitazones for respiratory disease treatment
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
CA2770873A1 (en) 2009-08-12 2011-02-17 Novartis Ag Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
ES2709108T3 (es) 2009-08-17 2019-04-15 Intellikine Llc Compuestos heterocíclicos y usos de los mismos
WO2011050325A1 (en) 2009-10-22 2011-04-28 Vertex Pharmaceuticals Incorporated Compositions for treatment of cystic fibrosis and other chronic diseases
GB0918924D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Azaindole derivatives
GB0918922D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminopyridine derivatives
GB0918923D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminothiazole derivatives
WO2011098746A1 (en) 2010-02-09 2011-08-18 Pulmagen Therapeutics (Inflammation) Limited Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone
GB201002224D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
GB201002243D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
BR112013007469B1 (pt) * 2010-09-21 2020-03-31 Intekrin Therapeutics, Inc. Composições farmacêuticas antidiabéticas sólidas, seu uso e método de preparação, método para preparar um produto de granulação e composição precursora farmacêutica
JP2014505088A (ja) 2011-02-10 2014-02-27 ノバルティス アーゲー Ｃ−ＭＥＴチロシンキナーゼ阻害剤としての［１，２，４］トリアゾロ［４，３−ｂ］ピリダジン化合物
US9127000B2 (en) 2011-02-23 2015-09-08 Intellikine, LLC. Heterocyclic compounds and uses thereof
CA2828219A1 (en) 2011-02-25 2012-08-30 Irm Llc Pyrazolo [1,5-a] pyridines as trk inhibitors
US8883819B2 (en) 2011-09-01 2014-11-11 Irm Llc Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
UY34329A (es) 2011-09-15 2013-04-30 Novartis Ag Compuestos de triazolopiridina
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
ES2558457T3 (es) 2011-09-16 2016-02-04 Novartis Ag Compuestos heterocíclicos para el tratamiento de fibrosis quística
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
US9056867B2 (en) 2011-09-16 2015-06-16 Novartis Ag N-substituted heterocyclyl carboxamides
EP2793893A4 (en) 2011-11-23 2015-07-08 Intellikine Llc IMPROVED TREATMENT REGIMES USING MTOR INHIBITORS
US8809340B2 (en) 2012-03-19 2014-08-19 Novartis Ag Crystalline form
EP3964513A1 (en) 2012-04-03 2022-03-09 Novartis AG Combination products with tyrosine kinase inhibitors and their use
EP2906218B1 (en) * 2012-10-09 2016-12-14 Boehringer Ingelheim International GmbH Beta-2-adrenoceptor agonist for the treatment of cough
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
JP2016512835A (ja) 2013-03-15 2016-05-09 インテリカイン， エルエルシー キナーゼ阻害剤の組み合わせ及びそれらの使用
WO2015084804A1 (en) 2013-12-03 2015-06-11 Novartis Ag Combination of mdm2 inhibitor and braf inhibitor and their use
JP6433509B2 (ja) 2014-04-24 2018-12-05 ノバルティス アーゲー ホスファチジルイノシトール３−キナーゼ阻害薬としてのアミノピラジン誘導体
BR112016023967A2 (pt) 2014-04-24 2017-08-15 Novartis Ag derivados de pirazina como inibidores de fosfatidilinositol 3-cinase
KR20160145780A (ko) 2014-04-24 2016-12-20 노파르티스 아게 포스파티딜이노시톨 3-키나제 억제제로서의 아미노 피리딘 유도체
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
KR20170036037A (ko) 2014-07-31 2017-03-31 노파르티스 아게 조합 요법
JP2019536812A (ja) 2016-12-12 2019-12-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング オロダテロールとの同時投与による間質性肺疾患の処置方法に使用するためのニンテダニブ
CN110114346B (zh) 2016-12-20 2023-10-31 Inke股份公司 用于制备r-6-羟基-8-[1-羟基-2-[2-(4-甲氧基苯基)-1，1-二甲基乙基氨基乙基]-2h-1，4-苯并噁嗪-3(4h)-酮盐酸盐的改进方法
CN109096218B (zh) * 2018-08-06 2020-10-27 上海方予健康医药科技有限公司 盐酸奥达特罗晶型a及其制备方法
CN108997248B (zh) * 2018-08-06 2023-08-01 上海方予健康医药科技有限公司 盐酸奥达特罗晶型b及其制备方法
CN113891744A (zh) 2019-06-10 2022-01-04 诺华股份有限公司 用于治疗cf、copd和支气管扩张的吡啶和吡嗪衍生物
CA3146109A1 (en) 2019-08-28 2021-03-04 Novartis Ag Substituted 1,3-phenyl heteroaryl derivatives and their use in the treatment of disease
US11304897B2 (en) 2020-06-09 2022-04-19 Anovent Pharmaceutical (U.S.), Llc Pharmaceutical formulation containing umeclidinium bromide and vilanterol trifenatate
US11331322B1 (en) 2021-09-15 2022-05-17 Santen Pharmaceutical Co., Ltd. Medicament for preventing and/or treating dry eye

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0073505A1 (de) * 1981-09-01 1983-03-09 Boehringer Ingelheim Kg Neue Benzo-Heterocyclen
US4460581A (en) * 1982-10-12 1984-07-17 Boehringer Ingelheim Kg (1-Hydroxy-2-amino-alkyl)-substituted benzoxazinones and benzoxazolinones
EP0321864A2 (de) * 1987-12-19 1989-06-28 Boehringer Ingelheim Kg Neue Ammoniumverbindungen, ihre Herstellung und Verwendung

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2405745A1 (en) * 2000-04-27 2001-11-08 Boehringer Ingelheim Pharma Kg New betamimetics having a long-lasting activity, processes for preparingthem and their use as medicaments

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0073505A1 (de) * 1981-09-01 1983-03-09 Boehringer Ingelheim Kg Neue Benzo-Heterocyclen
US4460581A (en) * 1982-10-12 1984-07-17 Boehringer Ingelheim Kg (1-Hydroxy-2-amino-alkyl)-substituted benzoxazinones and benzoxazolinones
EP0321864A2 (de) * 1987-12-19 1989-06-28 Boehringer Ingelheim Kg Neue Ammoniumverbindungen, ihre Herstellung und Verwendung

Also Published As

Publication number Publication date
TW200423943A (en) 2004-11-16
UA81276C2 (en) 2007-12-25
ME00354B (me) 2011-10-10
KR101092247B1 (ko) 2011-12-12
CY2014032I1 (el) 2015-12-09
JP4317138B2 (ja) 2009-08-19
IL167900A (en) 2013-06-27
NO2014005I1 (no) 2014-03-10
MXPA05005081A (es) 2005-07-01
ECSP055774A (es) 2005-11-22
ZA200502246B (en) 2006-01-25
HUS1400011I1 (hu) 2022-02-28
BE2014C016I2 (enrdf_load_stackoverflow) 2023-03-07
EP1562603A2 (de) 2005-08-17
NO20052883L (no) 2005-06-14
EP2025338A1 (de) 2009-02-18
TWI343812B (en) 2011-06-21
ATE430569T1 (de) 2009-05-15
NZ540661A (en) 2007-12-21
BRPI0316264B8 (pt) 2021-05-25
FR14C0049I2 (fr) 2015-07-24
FR14C0049I1 (enrdf_load_stackoverflow) 2014-08-08
RS51607B (sr) 2011-08-31
HRP20050432A2 (en) 2006-06-30
NL300650I2 (nl) 2017-11-02
PL212238B1 (pl) 2012-08-31
ES2326878T7 (es) 2014-03-11
AR087241A2 (es) 2014-03-12
PL375270A1 (en) 2005-11-28
CA2506082A1 (en) 2004-06-03
CO5570670A2 (es) 2005-10-31
EP1562603B3 (de) 2014-01-08
RS20050361A (sr) 2007-04-10
DK1562603T3 (da) 2009-09-07
PE20040694A1 (es) 2004-11-23
BRPI0316264B1 (pt) 2019-04-09
EA200500715A1 (ru) 2005-12-29
AU2003285326B2 (en) 2009-06-04
EA008665B1 (ru) 2007-06-29
EP1562603B1 (de) 2009-05-06
WO2004045618A3 (de) 2004-09-30
CY2014032I2 (el) 2015-12-09
MEP53608A (en) 2011-05-10
ES2326878T3 (es) 2009-10-21
CN1713914A (zh) 2005-12-28
KR20050075013A (ko) 2005-07-19
CN101817800A (zh) 2010-09-01
CA2506082C (en) 2011-06-21
AU2003285326A1 (en) 2004-06-15
LU92433I2 (fr) 2014-06-24
SI1562603T1 (sl) 2009-10-31
BR0316264A (pt) 2005-10-11
NO334314B1 (no) 2014-02-03
LTC1562603I2 (lt) 2016-12-12
DE50311502D1 (de) 2009-06-18
AR041969A1 (es) 2005-06-01
MY136034A (en) 2008-07-31
DE10253282A1 (de) 2004-05-27
PT1562603E (pt) 2009-06-18
WO2004045618A2 (de) 2004-06-03
JP2006508140A (ja) 2006-03-09
CN101735166A (zh) 2010-06-16
CY1110500T1 (el) 2015-04-29

Similar Documents

Publication Publication Date Title
HRP20050432B1 (en) Novel medicaments for the treatment of chronic obstructive pulmonary diseases
SE0202463D0 (sv) Novel compounds
IS2696B (is) Setin 2-amínótetralín fyrir meðhöndlunina á geðdeyfð
ES2195785A1 (es) Nuevos derivados de piridazin-3(2h)-ona.
SE0101387D0 (sv) Novel compounds
WO2006005609A3 (de) Substituierte oxindol-derivate und diese enthaltende arzneimittel
NO20044995L (no) Heterosykliske forbindelser
NO20044866L (no) Pyrazolo-pyrimidin-anilin-forbindelser anvendelige som kinase-inhibitorer
TNSN03110A1 (en) Azaindoles.
SE0202429D0 (sv) Novel Compounds
DE60315674D1 (de) Neue imidazopyridine und ihre verwendung
ATE477256T1 (de) Thienylverbindungen
ECSP055533A (es) Compuestos de fenilsulfonamida sustituida inhibidores de la producción de beta-amiloide
GB0314967D0 (en) Piperazine derivatives
SE9701304D0 (sv) Compounds
MX2008001778A (es) Combinacion de un agente hipnotico y un compuesto de bis arilo y heteroarilo sustituido y aplicacion terapeutica de la misma.
RS50229B (sr) Analozi vitamina d3
SE9803773D0 (sv) Compounds
MX2009013003A (es) Derivados de piperidina-amida.
SE0203302D0 (sv) Novel Compounds
NO20033801L (no) Karbamatforbindelser for anvendelse ved forebygging eller behandling av psykotiske forstyrrelser
MXPA03010205A (es) Derivados de acido oxalico.
DE60215918D1 (de) Azofarbstoffe
AU2001234314A1 (en) Novel phenylheteroalkylamine derivatives
MXPA04001121A (es) Derivados de fenilo.

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20181106

Year of fee payment: 16

ODRP Renewal fee for the maintenance of a patent

Payment date: 20191022

Year of fee payment: 17

ODRP Renewal fee for the maintenance of a patent

Payment date: 20201102

Year of fee payment: 18

ODRP Renewal fee for the maintenance of a patent

Payment date: 20211109

Year of fee payment: 19

ODRP Renewal fee for the maintenance of a patent

Payment date: 20221107

Year of fee payment: 20

PB20 Patent expired after termination of 20 years

Effective date: 20231111